Weight loss and improved metabolic health can reduce cardiovascular risks and enhance overall fitness, potentially making you a better candidate for future donation once treatment stabilises
Lipolytic and Insulinotropic Effects of HM12525A, A Novel Long-Acting GLP-1/Glucagon Dual Agonist
Dheeraj Kapoor, head, endocrinology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, adds, These drugs are not a quick-fix at a population level
All types of GLP-1 RAs also showed therapeutic potential for MASLD, and the efficacy of semaglutide in MASLD was highlighted
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis
Learn more about these treatments on our healthy aging treatments page